| 1 | Preoperative chemoradiotherapy, pancreaticoduodenectomy, and external- beam intraoperative radiotherapy for pancreatic adenocarcinoma: The M.D. Anderson experience (Leach SD, Rich TA, Abbruzzese JL, Lee JE, Cleary KR, Katz RL, Charnsangavej C, Ames FC, Buchholz DJ, Fenoglio CJ, Stanford P, Evans DB) Cancer Bulletin 1994;46(6):518-524 3 Citations |
| 1 | Preoperative chemoradiation for adenocarcinoma of the pancreas: M.D. Anderson experience (Evans DB, Abbruzzese JL, Lee JE, Leach SD, Charnsangavej C, Cleary KR, Buchholz DJ, Rich TA) Seminars in Surgical Oncology March/April 1995;11(2):132-140 10 Citations |
| 1 | Multimodality therapy for adenocarcinoma of the pancreas: The M.D. Anderson experience (Evans DB, Pisters PWT, Lee JE) Problems in General Surgery June 1997;14(2):117-124 2 Citations |
| 1 | The M.D. Anderson Cancer Center experience with interferon-alpha therapy in chronic myelogenous leukaemia. (Talpaz M, Kantarjian HM, O'Brien S, Kurzrock R) Baillieres Clin Haematol 1997 Jun;10(2):291-305 13 Citations |
| 1 | Chronic myelogenous leukemia--progress at the M. D. Anderson Cancer Center over the past two decades and future directions: first Emil J Freireich Award Lecture. (Kantarjian HM, Talpaz M, O'Brien S, Kurzrock R, Gutterman J, Keating MJ, McCredie KB, Freireich EJ) Clin Cancer Res 1997 Dec;3(12 Pt 2):2723-33 16 Citations |
| 1 | Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series. (Tsimberidou AM, Giles F, Duvic M, Fayad L, Kurzrock R) Cancer 2004 Jan 15;100(2):342-9 73 Citations |
| 1 | Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience. (Tsimberidou AM, Giles FJ, Khouri I, Bueso-Ramos C, Pilat S, Thomas DA, Cortes J, Kurzrock R) Ann Oncol 2005 Jan;16(1):139-45 53 Citations |
| 1 | Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience. (Wheler J, Tsimberidou AM, Hong D, Naing A, Jackson T, Liu S, Feng L, Kurzrock R) Cancer 2009 Mar 01;115(5):1091-9 75 Citations |
| 1 | Clinical outcomes and factors predicting development of venous thromboembolic complications in patients with advanced refractory cancer in a Phase I Clinic: the M. D. Anderson Cancer Center experience. (Vemulapalli S, Chintala L, Tsimberidou AM, Dhillon N, Lei X, Hong D, Kurzrock R) Am J Hematol 2009 Jul;84(7):408-13 13 Citations |
| 1 | Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience. (Tsimberidou AM, Vaklavas C, Wen S, Hong D, Wheler J, Ng C, Naing A, Tse S, Busaidy N, Markman M, Sherman SI, Kurzrock R) J Clin Endocrinol Metab 2009 Nov;94(11):4423-32 30 Citations |
| 1 | Clinical outcomes of patients with breast cancer in a phase I clinic: the M. D. Anderson cancer center experience. (Wheler J, Tsimberidou AM, Moulder S, Cristofanilli M, Hong D, Naing A, Pathak R, Liu S, Feng L, Kurzrock R) Clin Breast Cancer 2010 Feb;10(1):46-51 |
| 1 | Phase I clinical trials in 85 patients with gynecologic cancer: the M. D. Anderson Cancer Center experience. (Moroney J, Wheler J, Hong D, Naing A, Falchook G, Bodurka D, Coleman R, Lu K, Xiao L, Kurzrock R) Gynecol Oncol 2010 Jun;117(3):467-72 14 Citations |
| 1 | Phase 1 clinical trials in 83 patients with pancreatic cancer: The M. D. Anderson Cancer Center experience. (Vaklavas C, Tsimberidou AM, Wen S, Hong D, Wheler J, Ng CS, Naing A, Uehara C, Wolff RA, Kurzrock R) Cancer 2011 Jan 01;117(1):77-85 7 Citations |
| 1 | Phase I clinical trial outcomes in 93 patients with brain metastases: the MD anderson cancer center experience. (Tsimberidou AM, Letourneau K, Wen S, Wheler J, Hong D, Naing A, Iskander NG, Uehara C, Kurzrock R) Clin Cancer Res 2011 Jun 15;17(12):4110-8 22 Citations |
| 1 | Prevalence of complementary medicine use in a phase 1 clinical trials program: the MD Anderson Cancer Center Experience. (Naing A, Stephen SK, Frenkel M, Chandhasin C, Hong DS, Lei X, Falchook G, Wheler JJ, Fu S, Kurzrock R) Cancer 2011 Nov 15;117(22):5142-50 55 Citations |
| 1 | Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center. (Garrido-Laguna I, Janku F, Vaklavas C, Falchook GS, Fu S, Hong DS, Naing A, Tsimberidou AM, Wen S, Kurzrock R) Cancer 2012 Mar 01;118(5):1422-8 90 Citations |
| 1 | Outcomes of research biopsies in phase I clinical trials: the MD anderson cancer center experience. (El-Osta H, Hong D, Wheler J, Fu S, Naing A, Falchook G, Hicks M, Wen S, Tsimberidou AM, Kurzrock R) Oncologist 2011;16(9):1292-8 59 Citations |
| 1 | Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience. (Wheler JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, Moulder S, Stephen B, Wen S, Kurzrock R) Ann Oncol 2012 Aug;23(8):1963-1967 18 Citations |
| 1 | Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience. (Wheler J, Tsimberidou AM, Hong D, Naing A, Falchook G, Piha-Paul S, Fu S, Moulder S, Stephen B, Wen S, Kurzrock R) Clin Cancer Res 2012 May 15;18(10):2922-9 93 Citations |
| 1 | Outcomes in 144 patients with colorectal cancer treated in a phase I clinic: the MD Anderson Cancer Center experience. (Hong DS, Patel JC, Wheler J, Naing A, Garrido-Laguna I, Falchook G, Fu S, Tsimberidou AM, Kopetz S, Win S, Kurzrock R) Clin Colorectal Cancer 2012 Dec;11(4):297-303 9 Citations |
| 1 | Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs. (Naing A, Veasey-Rodrigues H, Hong DS, Fu S, Falchook GS, Wheler JJ, Tsimberidou AM, Wen S, Fessahaye SN, Golden EC, Aaron J, Ewer MS, Kurzrock R) Ann Oncol 2012 Nov;23(11):2960-2963 42 Citations |
| 1 | Advance care planning in patients with cancer referred to a phase I clinical trials program: the MD Anderson Cancer Center experience. (Fu S, Barber FD, Naing A, Wheler J, Hong D, Falchook G, Piha-Paul S, Tsimberidou A, Howard A, Kurzrock R) J Clin Oncol 2012 Aug 10;30(23):2891-6 30 Citations |
| 1 | Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. (Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Luthra R, Ye Y, Wen S, Berry D, Kurzrock R) Clin Cancer Res 2012 Nov 15;18(22):6373-83 472 Citations |
| 1 | Thymoma patients treated in a phase I clinic at MD Anderson Cancer Center: responses to mTOR inhibitors and molecular analyses. (Wheler J, Hong D, Swisher SG, Falchook G, Tsimberidou AM, Helgason T, Naing A, Stephen B, Janku F, Stephens PJ, Yelensky R, Kurzrock R) Oncotarget 2013 Jun;4(6):890-8 40 Citations |
| 1 | Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population. (Wheler J, Falchook G, Tsimberidou AM, Hong D, Naing A, Piha-Paul S, Chen SS, Heymach J, Fu S, Stephen B, Fok JY, Janku F, Kurzrock R) Oncotarget 2013 May;4(5):772-84 19 Citations |
| 1 | Hepatic arterial infusion therapy in advanced cancer and liver-predominant disease: the MD Anderson Experience. (Tsimberidou AM, Vaklavas C, Fu S, Wen S, Lim JA, Hong D, Wheler J, Naing A, Uehara C, Wallace M, Kurzrock R) Hepatogastroenterology 2013 Oct;60(127):1611-23 11 Citations |
| 1 | Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses. (Tsimberidou AM, Wen S, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Aldape K, Ye Y, Kurzrock R, Berry D) Clin Cancer Res 2014 Sep 15;20(18):4827-36 181 Citations |
| 1 | Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents. (Ganesan P, Moulder S, Lee JJ, Janku F, Valero V, Zinner RG, Naing A, Fu S, Tsimberidou AM, Hong D, Stephen B, Stephens P, Yelensky R, Meric-Bernstam F, Kurzrock R, Wheler JJ) Mol Cancer Ther 2014 Dec;13(12):3175-84 34 Citations |
| 1 | Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic. (Jardim DL, Tang C, Gagliato Dde M, Falchook GS, Hess K, Janku F, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, Holla V, Li MM, Roy-Chowdhuri S, Luthra R, Salgia R, Kurzrock R, Meric-Bernstam F, Hong DS) Clin Cancer Res 2014 Dec 15;20(24):6336-45 77 Citations |
| 1 | Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: the university of Texas MD anderson cancer center experience. (Corrales-Medina FF, Herzog C, Hess K, Egas-Bejar D, Hong DS, Falchook G, Anderson P, Nunez C, Huh WW, Naing A, Tsimberidou AM, Wheler J, Paul SP, Janku F, Kleinerman ES, Kurzrock R, Subbiah V) Oncoscience 2014 Jul 27;1(7):522-530 7 Citations |
| 1 | Parathyroid carcinoma and atypical parathyroid neoplasms in MEN1 patients; A clinico-pathologic challenge. The MD Anderson case series and review of the literature. (Christakis I, Busaidy NL, Cote GJ, Williams MD, Hyde SM, Silva Figueroa AM, Kwatampora LJ, Clarke CN, Qiu W, Lee JE, Perrier ND) Int J Surg 2016 Jul;31:10-6 50 Citations |
| 1 | Outcomes of patients ≥65 years old with advanced cancer treated on phase I trials at MD ANDERSON CANCER CENTER. (Subbiah IM, Wheler JJ, Hess KR, Hong DS, Naing A, Fu S, Kurzrock R, Tsimberidou AM) Int J Cancer 2017 Jan 01;140(1):208-215 12 Citations |
| 1 | Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study. (Tsimberidou AM, Hong DS, Ye Y, Cartwright C, Wheler JJ, Falchook GS, Naing A, Fu S, Piha-Paul S, Janku F, Meric-Bernstam F, Hwu P, Kee B, Kies MS, Broaddus R, Mendelsohn J, Hess KR, Kurzrock R) JCO Precis Oncol 2017;2017 143 Citations |
| 1 | How to Build a Successful Phase I Clinical Trials Unit: Lessons Based on the MD Anderson Cancer Center Experience. (Kurzrock R, Hong D) J Immunother Precis Oncol 2024 Aug;7(3):142-149 1 Citation |
